This article was originally published in The Tan Sheet
FDA has approved Clarinex-D 12-Hour extended release tablets, Schering announces Feb. 1. The new formulation (desloratadine 2.5 mg/pseudoephedrine sulfate 120 mg) features a bi-layer tablet delivery system to control the release of the pseudoephedrine. The drug will be available in March, in time for allergy season, Schering notes. Separately, Claritin sales decreased 29% to $54 mil. during the fourth quarter of 2005, the company reports in an earnings call Jan. 30. Decreased Claritin-D (loratadine/pseudoephedrine) sales were attributed to PSE retail restrictions. Lower Claritin revenues, as well as a dip in sales of other pseudoephedrine-containing products contributed to a 9% decline in Consumer Health Care sales from the prior-year period to $198 mil. for the quarter. Adjusted net sales for the firm overall increased 13% to $2.7 bil. in the quarter, signaling the firm's move "from survive mode into thrive mode," CEO Fred Hassan states...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.